Stem-Cell Treatment for Liver Disease :EHSI Forms Joint Venture

EHSI Forms Joint Venture to Develop Stem-Cell Treatment for Liver Disease

Published: Tuesday, 18 Jan 2011 9:15 AM ET Text Size
HOUSTON, Jan 18, 2011 (BUSINESS WIRE) -- Emerging Healthcare Solutions, Inc.

(PinkSheets: EHSI) announced today that it has entered into a joint venture agreement with its wholly owned subsidiary, Celulas Genetica, in order to pursue testing of the revolutionary Rutherford Procedure using a NASA bioreactor.

Celulas Genetica obtained a license to develop and market the Rutherford Procedure from the Chinese firm BBFITCL. The Rutherford Procedure is a groundbreaking organ regeneration treatment being developed to utilize proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells. EHSI acquired Celulas Genetica last December.

Testing and marketing of the Rutherford Procedure are central to EHSI's plans for its NASA-developed bioreactor. The company's Intrifuge Rotary Cell Culture System(TM) is a rotating-wall bioreactor originally designed by NASA to facilitate the growth of human cells in simulated weightlessness. Cell cultures--including stem cells--grown inside the bioreactor look and function much closer to human cells grown within the body than cell cultures grown in Petri dishes. Adult stem cell production is a crucial component of the Rutherford Procedure, and the NASA bioreactor will be able to provide the quality and quantity of stem cells necessary for research and development.

"We are very serious about developing the Rutherford Procedure into a viable treatment for liver disease," said EHSI President and CEO Cindy Morrissey. "Our research on the procedure and on proton-beam centers world-wide has convinced us that China is the best place to pursue further testing and trials." EHSI owns a license to use the bioreactor to expand adult stem cells in China and elsewhere outside of the U.S. Extending its reach into the R&D hotbed of China would build on EHSI's rapidly expanding global footprint--Celulas Genetica is headquartered in Panama, and Morrissey opened EHSI business offices in Poland and Germany last November.

EHSI invests in technology developed to compete in the stem-cell research industry alongside Dendreon Corp. (NASDAQ:DNDN), Gilead Sciences (NASDAQ:GILD), Celgene Corp. (NASDAQ:CELG) and Biogen Idec Inc. (NASDAQ:BIIB).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.

For more information, please visit http://www.EmergingHealthcareSolutionsInc.com .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

SOURCE: Emerging Healthcare Solutions, Inc.

CONTACT: Emerging Healthcare Solutions, Inc. Cindy Morrissey, 713-821-1486 President and CEO Copyright Business Wire 2011 -0- KEYWORD: United States

China

Asia Pacific

North America

Texas INDUSTRY KEYWORD: Stem Cells

Health

Biotechnology SUBJECT CODE: Contract/Agreement
http://classic.cnbc.com/id/41133031